Sex steroid receptors act as ligand activated nuclear transcription factors throughout the body, including the brain. However, post-translational modification of these receptors can direct them to extranuclear sites, including the plasma membrane, where they are able to initiate rapid signaling. Because of the conserved domain structure of these receptors, alternative exon splicing can result in proteins with altered nuclear and extranuclear actions. Although much attention has focused on internal and C-terminal splice variants, both estrogen and androgen receptors undergo N-terminal truncations, as well. These truncated proteins not only influence the transcriptional activity of the full-length receptors, but also associate with caveolin and initiate signaling at the plasma membrane. Such actions may have important physiological consequences in neuronal, endothelial, and cancer signaling and cell survival.
Introduction
Receptors for androgens, estrogens, and progestins (ARs, ERs, PRs) belong to the steroid receptor superfamily of nuclear transcription factors that share a common structural organization (for reviews see: [1] [2] [3] ). The defining feature of these receptors is a three domain structure centered around two zinc finger motifs in the DNA binding domain (DBD) that allow interaction with specific promoter elements termed hormone responsive elements (HREs). The carboxy-terminal domain (CTD) contains the ligand binding domain (LBD) and ligand dependent activation function 2 (AF2), the region responsible for recruiting coactivators and interacting with the basal transcriptional machinery to initiate activation of regulated genes. The amino-terminal domain (NTD) is the most variable region, and is primarily associated with the ligand-independent activation function 1 (AF1), that also interacts with AF2 in the ligand-activated state. In addition to direct DNA binding, these receptors can regulate transcription through proteinprotein interactions with other transcription factors to modulate their activity.
As nuclear transcription factors, sex steroid receptors (SRs) are primarily localized to the nucleus, but nuclear-cytoplasmic shuttling and post-translational modifications act to localize a portion of SRs to the plasma membrane. The best-described examples of these actions are from cancer and endothelial cells that demonstrate a small proportion of SRs are trafficked to the plasma membrane through palmitoylation of the CTD [4] and interactions with caveolin-1 [5] [6] [7] . A role for rapid steroid actions in neurons has been recognized since the 1970's, but the nature of the receptors underlying the various effects of steroids in the brain continues to evolve [8] .
In addition to trafficking of full-length receptors to the membrane and the discovery of structurally unrelated membrane SRs, evidence from studies of ERs and PRs supports a role for N-terminal truncated receptors as mediators of extra-nuclear and membrane actions. Recent evidence from our [9, 10] lab supports the role of membrane-associated NTD truncated androgen receptor in membrane lipid rafts of neurons (Fig. 1) . In this mini-review, we examine the potential role of SR NTD splice variants in rapid neuronal signaling (Fig. 2 ).
Steroid receptor splice variants
In addition to steroid receptor isoforms encoded by different genes (i.e. ERα, ERβ) steroid receptors undergo extensive alternative splicing [11] . Alternative 5′ untranslated regions (UTRs)/exons appear to be a common characteristic of SRs including glucocorticoid receptors [12, 13] , mineralocorticoid receptors [14, 15] , ERs [16] [17] [18] , and ARs [19] . In most cases, these alternative exon sequences do not affect the coding sequence of the SR, but rather tissue specific distribution or expression levels. However, as discussed below, in some cases, alternative splicing of the NTD yields SRs with altered expression, localization, and function. With respect to the functional properties of SR splice variants, those that result in changes to the coding region have been the subject of more study. Numerous splice variants in the coding sequence of SRs have been detected in peripheral tissues, and are abundant in cancer cells. For example, the sensitivity of RT-PCR allows the detection of 18 different ERα splice variants and 17 different PR splice variants in the human endometrium [20, 21] and brain [22] . Depending on the exon(s) spliced out of the coding sequence, these splice variants can result in transcripts that produce either functional or non-functional proteins. The domain structure of SRs and the close overlap of exons with functional domains allow functional splice variants to act as constitutively active, dominant negative, or modulatory factors for full-length receptors [11] . Some of these variants result in internal start codons that produce functional proteins. However, beyond their transcriptional actions, SR variants may also mediate various non-genomic actions depending on their ability to interact with cytoplasmic and membrane proteins through their remaining domains.
Estrogen receptor NTD splice variants
Using RT-PCR, numerous ERα splice variants have been detected in the rat and human brain. In the rat brain, these include deletions of exon 3 [23] , exon 4 [24, 25] , exons 3/4 [25] , and exons 5/6 [25] . Alternative promoter expression can also result in an NTD truncation of exon 1 in ERα [26] . This deletion produces a 46 kDa protein (ERα46) from a start codon early in exon 2, and is also found in mice and humans [26] . In transfected cells overexpressing ERα46, this variant appears predominantly nuclear and can stimulate transcription in response to estrogen, but inhibits the activity of the full-length ERα66 [26] . However, in human endothelial cells ERα46 localizes to the plasma membrane, where it can mediate the estrogen-induced stimulation of endothelial nitric oxide synthase (eNOS) through interactions with PI3 kinase [27, 28] . Similarly, ERα46 interacts with PI3K p85a subunit in rat cerebral cortex and this interaction declines with age [29] . ERα46 and additional isoforms are also localized to rat cerebral endothelial cells [30] , but it is unclear whether it is localized to neurons.
A second major NTD truncated ERα, first noted in endometrium [27] and cloned from human breast tumors [31] , is ERα36. Like ERα46, ERα36 lacks exon 1 [27, [31] [32] [33] . However, it also skips exons 6 and 7 of the full-length ERα and has a unique 27 amino acid CTD [33] . Thus, the resulting protein lacks both the AF1 and much of the AF2/LBD. In the breast, ERα36 is predominantly localized to the plasma membrane where it mediates estrogen activation of MAPK and PI3/Akt signaling [34, 35] . Further evidence from transfection experiments supports a role for ERα36 in the mobilization of calcium in breast cancer cells [36] . In addition to its role at the membrane, there is also evidence that ERα36 can inhibit transcriptional activation by the full-length ERα66 [34] . Although initially found in peripheral tissues, ERα36 has also been localized to neurons in the cortex and hippocampus of rats where it is mostly extra-nuclear [37] . In both the rat and human brain ERα36 is associated with caveolin-1 in cortical and hippocampal neurons, confirming membrane localization [37] . Ovariectomy and cerebral Fig. 1 . N27 dopaminergic cells derived from fetal rat mesencephalic tissue express AR45 protein in membrane lipid rafts. N27 cells were treated with 100 nM testosterone for 24 h to stabilized the androgen receptor. N27 cells were homogenized and separated into membrane, cytosol, and nuclear fractions. The membrane portion of the cells were further separated into 9 fractions using a sucrose gradient and ultracentrifugation in order to examine lipid rafts. Primary antibodies targeting AR45 (Santa Cruz sc-815/AR-C19 androgen receptor antibody) and lipid raft markers (Cell Signaling 3267 caveolin-1 antibody) were used. AR45 was only observed in caveolin positive lipid raft fractions. N = 3 per treatment group. 
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Steroids 133 (2018) [15] [16] [17] [18] [19] [20] ischemia both appear to reduce ERα36 levels in the rat hippocampus, and actions of a selective agonist for ERα36 suggest that it may be involved in neuroprotection afforded by estrogen and tamoxifen [37, 38] . In human neuroblastoma cells, knockdown of ERα36 attenuates estrogen-induced activation of MAPK and Akt and neuroprotection against H 2 O 2 toxicity, further supporting a rapid signaling and protective role for this splice variant [39] . In addition to neurons, ERα36 is also found in glioblastoma cells where it may be involved in tamoxifen resistance [40] . A third NTD splice variant, termed MB-1, has also been observed in the human brain [41] . MB-1 lacks 168 nucleotides in the middle of exon 1, significantly reducing transcriptional activity [42] . Antibodies raised against MB-1 demonstrate that it present in astrocytes, endothelial cells, and neurons in several areas of the human brain including the hypothalamus, hippocampus, and amygdala and appears primarily cytoplasmic [43] . A role for MB-1 in rapid estrogen signaling has not been examined.
In rodents, truncated estrogen receptor products (TERPs) lacking exons 1-4 and having unique untranslated N-terminal region were first identified in the rat pituitary [44] . In the mouse TERPs transcripts are present in several tissue, including the brain [45] . An internal start codon in exon 5 leads to the production of a protein containing most of the LBD. TERPs have been localized to both the nucleus [46] and extranuclear compartments [45] . TERPs show some basal transcriptional activity and can inhibit transcriptional actions of both ERα and ERβ [45] [46] [47] . However, rapid effects of these truncated receptors have not been examined.
Several splice variants of the ERβ are also present in the human and rodent brain. However, in the human all of the variants identified are truncations of the CTD [48] and result in dominant negative transcriptional effects on full length ERs [49] . Similarly, several ERβ splice variants have been detected in the rat brain, including both insertions and deletions [50] . However, like the human, none of the variants identified thus far include truncations of the NTD, and all except ERβ1Δ4 appear nuclear [50, 51] .
The membrane-dependent actions of estrogens are not solely dependent on the classical ERs, as other ER-binding proteins, namely the G protein-coupled ER, can mediate rapid effects on kinase signaling [52, 53] .
Progesterone receptor NTD splice variants
Alternate translational start sites in the PR gene lead to the expression of two functional proteins, PR-A and PR-B. PR-B has an additional 165 amino acids at the N-terminus and an additional activation domain, AF-3 [54] . Both isoforms are expressed in neurons in addition to a large number of splice variants [55, 56] . As such, PR-A can be considered an NTD partial deletion. However, rapid extranuclear actions of progesterone, including activation of MAPK, appear to be mediated by PR-B, rather than PR-A [57,58] even though both isoforms have an Src-interacting domain that is able to bind Src and activate MAPK [59] . Despite clear evidence for rapid membrane actions mediated through PR-A and PR-B [60] , the role of N-terminal splice variants is less clear. In contrast, most CTD variants act as dominant negative regulators of the nuclear effects of PR-A and PR-B [61] . Three additional NTD deleted PRs have been identified in peripheral tissues including one lacking exon 1 (PR-C), and two lacking exons 1-3 (PR-S and PR-T) [55, 56] . PR-S and PR-T transcripts contain different intronic 5′UTRs, but would likely produce the same AF1/AF3/DBD deleted protein from an internal start codon in exon 4 [55] . An additional Nterminal truncated PR with a potential signal peptide, PR-M, was also cloned from a human aortic cDNA library [62] . However, careful analysis by Samalecos and Gellersen suggest that none of the proposed NTD truncated variants produced functional proteins [63] . In ultrastructural studies extra-nuclear PRs are found in neurons and glial cells in the rat and mouse brain [64, 65] , but the nature of these PRs is not known since the antibodies used in these studies would detect PR-A, PR-B, and NTD truncated variants. Evidence for several additional progesterone-activated membrane receptors, suggests that the rapid actions of progestins may not depend on membrane trafficking of the classical PRs [66] . Instead, additional progesterone-binding proteins (mPRs) originally identified in fish have been localized in humans and several other vertebrates [67] . Among these 7-transmembrane proteins is mPRβ, which appears to be enriched in the human brain [67] and at least three mPRs that are present in the rodent spinal cord, including in glia and neurons [68, 69] , and the PR membrane component, PGRMC1, that is widely expressed in the brain [70] .
Androgen receptor NTD splice variants
Increasing evidence strongly supports AR involvement in rapid nongenomic signaling, such as membrane-associated AR (mAR) activation of different signaling cascades in peripheral cell types. Common signaling cascades initiated by mAR include intracellular calcium release via the phospholipase C (PLC) pathway and G-protein coupled receptor signaling [71] [72] [73] [74] [75] [76] [77] . Similarly, non-genomic AR action has been observed in the brain. Studies have shown that a neuronal mAR can also activate several signaling pathways involved in intracellular calcium release, oxidative stress, cell survival, inflammation, and even pathways associated with addiction [10, [78] [79] [80] [81] [82] [83] [84] . Interestingly, the classical antagonist for the AR (flutamide) does not alter membrane-associated AR's nongenomic effects, regardless of cell type [10, 80, 83, 85] . Therefore, the membrane-associated AR may have a different structure or confirmation than the classical AR.
Splice variants have been proposed as candidates for the mAR. Since the mAR is responsive to androgenic agonists, the AR splice variant must contain a ligand binding domain. Only two AR splice variants, AR8 and AR45, meet this qualification. These two AR splice variants have truncated N-terminal domains [86] [87] [88] [89] . AR8 has only been observed in prostate cell lines, and has no transcriptional activity due to lacking a DNA binding domain. AR8 function is unknown but AR8 is proposed to be associated with non-genomic signaling, since it is localized to the plasma membrane via palmitoylation [89, 90] . AR45 splice variant seems to have cell specific localization. In peripheral cells, AR45 can dimerize with full length AR and act as a negative regulator via competitive inhibition of the ARE [88] . Interestingly, AR45 is the only reported splice variant in the brain. In contrast to peripheral cells, we show that neuronal AR45 localizes to caveolin positive lipid rafts in the plasma membrane ( Fig. 1) and interacts with G-protein coupled receptor signaling that can initiate intracellular calcium release [9] . Furthermore, studies using cell-impermeable androgens in a neuronal cell line containing membrane-associated AR45 found rapid non-genomic signaling that was unaffected by classical AR antagonists [9, 10, 80] . Therefore, it is plausible that the neuronal mAR could be AR45.
Ligands of NTD deleted SR splice variants
In addition to the cognate ligands shown to activate membrane-initiated signaling at membrane SRs, membrane effects of androgens and estrogens have been explored with cognate ligands coupled to large membrane impermeable molecules, such as bovine serum albumin (BSA). These conjugates have helped to distinguish membrane actions from those associated with cytoplasmic or nuclear actions. Thus, membrane ERs are activated by BSA-estradiol and membrane ARs are activated by BSA-testosterone. Currently, no antagonist has been found to block membrane associated AR, regardless of cell type [10, 80, 83, 85, [91] [92] [93] [94] [95] or ER [96] . In contrast to AR, the ER antagonist ICI 182,780 has no effect on eNOS activity in ERα46 transfected cells, but can inhibit estrogen and BSA-estrogen activated membrane ERα46 [27] . Unlike ERα46, the estrogen receptor antagonists tamoxifen and ICI 182,780 can both act as agonists for ERα36 to stimulate kinase signaling in breast cancer [32, 35] and neurons [38] despite the fact that part of the LBD is missing.
Most of the SR antagonists are targeted to the ligand binding domain located in the CTD of the receptor [97] indicating that the ligand binding domain may not be accessible to the SR antagonist. Interestingly, prior studies have shown that the plasma membrane can alter agonist and antagonist kinetics of receptors due to surrounding proteinprotein interactions [98, 99] . For example, a study using the same full length ER cDNA in several cell lines with diverse cellular localization observed different ER agonist and antagonist responses that was dependent on where the ER was localized within the cell [100] . Similarly, inhibition of AR45, AR splice variant missing NTD, by antagonists is dependent on cellular localization. The AR antagonist, flutamide, via binding to the LBD can block nuclear AR45 action in HEK293 and CHO cells [101] . However, flutamide was unable to inhibit plasma membrane AR45 action in a neuronal cell line [10, 80] .
Since it possible that the LBD of SRs located within the plasma membrane is not accessible to antagonists, other binding sites of the SR need to explored. Targeting the NTD domain of the SR for antagonists is a current area of research. However, NTD targeted SR antagonists are not appropriate for SRs that lack the NTD. Little progress has been made at targeting SR antagonists outside of the ligand binding domain and the NTD, due to the close similarity of the DBD regions between all the SRs [102] . Recently investigators have discovered a unique residue sequence in the AR DBD that can be targeted [97, [103] [104] [105] , which has been shown to inhibit full length AR and an AR splice variant missing only the ligand binding domain. DBD targeted AR antagonists have not been examined on the function of splice variants missing the NTD or in splice variants localized to the plasma membrane.
Conclusion
Depending on cellular localization, N-terminal truncated SRs can have diverse effects ranging from transcription to modulating rapid cell signaling. Indeed, these understudied truncated proteins may have important physiological consequences that can influence cell survival. Further, these proteins could be potential therapeutic targets for disorders that no longer respond to conventional treatments that target full length SRs, such as cancer.
